Nema internetske veze — prikazuje spremljenu verziju stranice.

HUTCHMED DRC

USUSD
← Na filtar dionica

HUTCHMED DRC (US:HCM) — Biotechnology: Pharmaceutical Preparations. Broj burzi na kojima se trguje dionicama tvrtke: 3. Na ovoj stranici — cijena i grafikon, dividende, najveći dioničari i povijest broja dionica.

O tvrtki

Web-stranica
hutch-med.com
Sektor
Health Care · Biotechnology: Pharmaceutical Preparations
Sjedište
Hong Kong, Hong Kong
Glavni direktor
Mr. Chig Fung Cheng BEc, CA
Zaposlenici
1 790
Osnovana
2000
Dionice u optjecaju
173.81 mil. na dan 2025-12-31
1 godina: +0.08% · 3 godine: +0.9% · 5 godina: +19.9% (bez podjela dionica)
DatumDionicePromjena
31.12.2025872.33 mil.+0.08%nema značajnih promjena
31.12.2024871.6 mil.+0.04%nema značajnih promjena
31.12.2023871.26 mil.+0.7%izdavanje (razrjeđivanje)
31.12.2022864.78 mil.+0.03%nema značajnih promjena
31.12.2021864.53 mil.+18.8%izdavanje (razrjeđivanje)
31.12.2020727.72 mil.+9.1%izdavanje (razrjeđivanje)
31.12.2019666.91 mil.podjela 10:1
31.12.201866.66 mil.+0.3%izdavanje (razrjeđivanje)
31.12.201766.45 mil.+9.5%izdavanje (razrjeđivanje)
31.12.201660.71 mil.
Broj dijeljenja iz izvještaja tvrtke. Podjela se detektira skokom u broju za puni broj puta.
Slobodno prenosive dionice
104.57 mil.
Tržišna kapitalizacija
2.46 mlrd. USD
Insajderi
0.01%
Institucionalni ulagači
2.61%
ISIN
KYG4672N1198
Omjer isplate
0%
FCF
9.95 mil. USD
Dug
97.9 mil. USD
2.2 g. FCF
Niz dividendi
—
Opis

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to treat pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.

Burze i oznake

BurzaOznakaValutaCijenaVrsta
US USA StocksHCMUSD14.2 -2.54%obične dionice
US USA StocksHMDCFUSD2.16obične dionice
LSE London Stock ExchangeHCMGBP2.09 -3.24%obične dionice

Cijena za 3 mjeseca

dan rasta dan pada ex-dividendni datum datum isplatePrelet / dodir jednog dana — otvori, zatvori, najviša i najniža cijena

Dividende

Nema isplate dividendi (provjereno 04.10.2026). Tvrtka vjerojatno ne isplaćuje dividende.

oglas

Najveći imatelji

ImateljUdioDioniceDatum izvješća
Schroder Investment Mana…0.85%1.48 mil.2026-06-30
Allianz Asset Management…0.39%674 5112026-06-30
State Street Corporation0.18%313 6112026-06-30
Aia Group Ltd0.17%291 2292026-06-30
M&G Plc0.14%242 7912026-06-30
Amundi0.12%204 3852026-06-30
Jane Street Group, LLC0.11%194 4722026-06-30
Renaissance Technologies…0.07%130 2002026-06-30
BNP Paribas Financial Ma…0.06%104 4252026-06-30
XY Capital Ltd0.06%104 1302026-06-30
Steward Funds Inc-Stewar…0.05%84 0972026-07-31
SPDR INDEX SHARES Fd.S-S…0.04%71 2422026-08-31
Tema ETF Trust-Tema Onco…0.04%67 8232026-05-31
-SSgA SPDR ETFS Europe I…0.02%41 5372026-07-31
Fidelity Concord Street…0.01%21 0322026-07-31
Dimensional ETF Trust-Di…0%7 8222026-04-30
Northern Lights Fd. TRT…0%7 5122026-05-31
DFA INVESTMENT DIMENSION…0%6 4692026-04-30
DFA INVESTMENT DIMENSION…0%6 2292026-04-30
DFA INVESTMENT TRUST CO-…0%3 3242026-04-30
Hutchison Whampoa———

Događaji kod regulatora

DatumRegulatorDogađajDetalji
2026-10-02ESMAоновлення даних інструментаISIN, майданчик HAND